Abstract
The search of new therapeutic tools and more intensive development of old ones are required to ensure effective treatment of various diseases. The usage of nanoparticles opens up future prospects for their involvement in the formulations of newly created biomaterials. They are widely applied for the targeted drug delivery, solving the diagnostic and therapeutic tasks. Nanoparticles have a significant set of factors that ensure their superiority over the conventional methods of the treatment. Among them are the ability to bypass biological barriers, a variety of pharmacokinetic profiles, and accurate delivery to the target tissue. This review discusses the current and future research of lipid, polymer, organic, and viral nanoparticles. In addition, the aspects related to the pharmacokinetics of nanoparticles during the application in vitro and their potential toxicity are considered in the area of clinical trials.
Keywords
- Diagnostics
- Nanoparticles
- Nanomedicine
- Theranostic
- Clinical use
This is a preview of subscription content, access via your institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Al-Hashedi AA, Laurenti M, Amine Mezour M, Basiri T, Touazine H, Jahazi M, Tamimi F (2019) Advanced inorganic nanocomposite for decontaminating titanium dental implants. J Biomed Mater Res–Part B Appl Biomater 107(3):761–772. https://doi.org/10.1002/jbm.b.34170
Baetke SC, Lammers T, Kiessling F (2015) Applications of nanoparticles for diagnosis and therapy of cancer. Br J Radiol 88(1054):20150207. https://doi.org/10.1259/bjr.20150207
Cutlip DE, Garratt KN, Novack V, Barakat M, Meraj P, Maillard L, Erglis A, Jauhar R, Popma JJ, Stoler R, Silber S, Cutlip D, Allaqaband S, Caputo R, Beohar N, Brown D, Garratt K, Jauhar R, George J, Varghese V, Huth M, Larrain G, Lee T, Malik A, Martin S, McGarry T, Phillips C, Shah A, Stoler R, Ball M, Price RJ, Rossi J, Taylor C, Tolleson T, Nicholson W, Kesanakurthy S, Shoukfeh M, Finn A, Devireddy C, Shoultz C, Robbins M, Kiesz R, Menon P, Weilenmann D, Sievert H, Stankovic G, Berland J, Delarche N, Hirsch JL, Maillard L, Shayne J, Serra A, Fernandez-Ortiz A, Monassier JP, Silber S (2017) 9-month clinical and angiographic outcomes of the COBRA Polyzene-F NanoCoated coronary stent system. JACC Cardiovasc Interv 10(2):160–167. https://doi.org/10.1016/j.jcin.2016.10.037
Deng H, Zhang Y, Yu H (2018) Nanoparticles considered as mixtures for toxicological research. J Environ Sci Heal–Part C Environ Carcinog Ecotoxicol Rev 36(1):1–20. https://doi.org/10.1080/10590501.2018.1418792
Duska LR, Krasner CN, O’Malley DM, Hays JL, Modesitt SC, Mathews CA, Moore KN, Thaker PH, Miller A, Purdy C, Zamboni WC, Lucas AT, Supko JG, Schilder RJ (2021) A phase Ib/II and pharmacokinetic study of EP0057 (formerly CRLX101) in combination with weekly paclitaxel in patients with recurrent or persistent epithelial ovarian, fallopian tube, or primary peritoneal cancer. Gynecol Oncol 160(3):688–695. https://doi.org/10.1016/j.ygyno.2020.12.025
Fries L, Cho I, Krähling V, Fehling SK, Strecker T, Hooper JW, Kwilas SA, Agrawal S, Wen J, Fix A, Thomas N, Flyer D, Smith G, Glenn G (2000) Randomized, blinded, dose-ranging trial of an Ebola virus glycoprotein nanoparticle vaccine with matrix-M adjuvant in healthy adults. J Infect Dis 222(4):572–582. https://doi.org/10.1093/infdis/jiz518
Guo Y, Bera H, Shi C, Zhang L, Cun D, Yang M (2021) Pharmaceutical strategies to extend pulmonary exposure of inhaled medicines. Acta Pharm Sin B 11(8):2565–2584. https://doi.org/10.1016/j.apsb.2021.05.015
Jiang Z, Shan K, Song J, Liu J, Rajendran S, Pugazhendhi A, Jacob JA, Chen B (2019) Toxic effects of magnetic nanoparticles on normal cells and organs. Life Sci 220:156–161. https://doi.org/10.1016/j.lfs.2019.01.056
Kalaydina RV, Bajwa K, Qorri B, Decarlo A, Szewczuk MR (2018) Recent advances in “smart” delivery systems for extended drug release in cancer therapy. Int J Nanomedicine 13:4727–4745. https://doi.org/10.2147/IJN.S168053
Ladaycia A, Passirani C, Lepeltier E (2021) Microbiota and nanoparticles: description and interactions. Eur J Pharm Biopharm 169:220–240. https://doi.org/10.1016/j.ejpb.2021.10.015
Li M, Zou P, Tyner K, Lee S (2017) Physiologically based pharmacokinetic (PBPK) modeling of pharmaceutical Nanoparticles. AAPS J 19(1):26–42. https://doi.org/10.1208/s12248-016-0010-3
Liu Y, Yang G, Jin S, Xu L, Zhao CX (2020) Development of high-drug-loading nanoparticles. Chempluschem 85(9):2143–2157. https://doi.org/10.1002/cplu.202000496
Mukai H, Kogawa T, Matsubara N, Naito Y, Sasaki M, Hosono A (2017) A first-in-human phase 1 study of epirubicin-conjugated polymer micelles (K-912/NC-6300) in patients with advanced or recurrent solid tumors. Investig New Drugs 35(3):307–314. https://doi.org/10.1007/s10637-016-0422-z
Mukherjee A, Waters AK, Kalyan P, Achrol AS, Kesari S, Yenugonda VM (2019) Lipid-polymer hybrid nanoparticles as a next generation drug delivery platform: state of the art, emerging technologies, and perspectives. Int J Nanomedicine 14:1937–1952. https://doi.org/10.2147/IJN.S198353
Najahi-Missaoui W, Arnold RD, Cummings BS (2021) Safe nanoparticles: are we there yet? Int J Mol Sci 22(1):1–22. https://doi.org/10.3390/ijms22010385
Nasirmoghadas P, Mousakhani A, Behzad F, Beheshtkhoo N, Hassanzadeh A, Nikoo M, Mehrabi M, Kouhbanani MAJ (2021) Nanoparticles in cancer immunotherapies: an innovative strategy. Biotechnol Prog 37(2):e3070. https://doi.org/10.1002/btpr.3070
Plucinski A, Lyu Z, Schmidt BVKJ (2021) Polysaccharide nanoparticles: from fabrication to applications. J Mater Chem B 9(35):7030–7062. https://doi.org/10.1039/d1tb00628b
Rodallec A, Benzekry S, Lacarelle B, Ciccolini J, Fanciullino R (2018) Pharmacokinetics variability: why nanoparticles are not just magic-bullets in oncology. Crit Rev Oncol Hematol 129:1–12. https://doi.org/10.1016/j.critrevonc.2018.06.008
Roncati L, Corsi L (2021) Nucleoside-modified messenger RNA COVID-19 vaccine platform. J Med Virol 93(7):4054–4057. https://doi.org/10.1002/jmv.26924
Roy S, Liu Z, Sun X, Gharib M, Yan H, Huang Y, Megahed S, Schnabel M, Zhu D, Feliu N, Chakraborty I, Sanchez-Cano C, Alkilany AM, Parak WJ (2019) Assembly and degradation of inorganic Nanoparticles in biological environments. Bioconjug Chem 30(11):2751–2762. https://doi.org/10.1021/acs.bioconjchem.9b00645
Saquib Nanoparticles T (2018) Overview, T. Transmucosal Nanoparticles, Toxicological Overview
Shinde V, Cai R, Plested J, Cho I, Fiske J, Pham X, Zhu M, Cloney-Clark S, Wang N, Zhou H, Zhou B, Patel N, Massare MJ, Fix A, Spindler M, Thomas DN, Smith G, Fries L, Glenn GM (2021) Induction of cross-reactive Hemagglutination inhibiting antibody and Polyfunctional CD4+ T-cell responses by a recombinant matrix-M-Adjuvanted hemagglutinin nanoparticle influenza vaccine. Clin Infect Dis 73(11):4278–4287. https://doi.org/10.1093/cid/ciaa1673
Subhan MA, Torchilin VP (2019) Efficient nanocarriers of siRNA therapeutics for cancer treatment. Transl Res 214:62–91. https://doi.org/10.1016/j.trsl.2019.07.006
Swartzwelter BJ, Fux AC, Johnson L, Swart E, Hofer S, Hofstätter N, Geppert M, Italiani P, Boraschi D, Duschl A, Himly M (2020) The impact of nanoparticles on innate immune activation by live bacteria. Int J Mol Sci 21(24):1–22. https://doi.org/10.3390/ijms21249695
Wicki A, Witzigmann D, Balasubramanian V, Huwyler J (2015) Nanomedicine in cancer therapy: challenges, opportunities, and clinical applications. J Control Release 200:138–157. https://doi.org/10.1016/j.jconrel.2014.12.030
Young JS, Bernal G, Polster SP, Nunez L, Larsen GF, Mansour N, Podell M, Yamini B (2018) Convection-enhanced delivery of polymeric Nanoparticles encapsulating chemotherapy in canines with spontaneous Supratentorial tumors. World Neurosurg 117:698–704. https://doi.org/10.1016/j.wneu.2018.06.114
Zahin N, Anwar R, Tewari D, Kabir MT, Sajid A, Mathew B, Uddin MS, Aleya L, Abdel-Daim MM (2020) Nanoparticles and its biomedical applications in health and diseases: special focus on drug delivery. Environ Sci Pollut Res 27(16):19151–19168. https://doi.org/10.1007/s11356-019-05211-0
Zhang X, Goel V, Attarwala H, Sweetser MT, Clausen VA, Robbie GJ (2020) Patisiran pharmacokinetics, pharmacodynamics, and exposure-response analyses in the phase 3 APOLLO trial in patients with hereditary transthyretin-mediated (hATTR) amyloidosis. J Clin Pharmacol 60(1):37–49. https://doi.org/10.1002/jcph.1480
Zhao J, Weng G, Li J, Zhu J, Zhao J (2018) Polyester-based nanoparticles for nucleic acid delivery. Mater Sci Eng C 92(11):983–994. https://doi.org/10.1016/j.msec.2018.07.027
Ziąbka M, Malec K (2019) Polymeric middle ear prosthesis enriched with silver nanoparticles–first clinical results. Expert Rev Med Devices 16(4):325–331. https://doi.org/10.1080/17434440.2019.1596796
Zylberberg C, Gaskill K, Pasley S, Matosevic S (2017) Engineering liposomal nanoparticles for targeted gene therapy. Gene Ther 24(8):441–452. https://doi.org/10.1038/gt.2017.41
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2023 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Osetrov, K., Morozkina, S., Snetkov, P., Uspenskaya, M. (2023). Nanoparticles at the Stage of Clinical Trials. In: Lamprou, D. (eds) Nano- and Microfabrication Techniques in Drug Delivery . Advanced Clinical Pharmacy - Research, Development and Practical Applications, vol 2. Springer, Cham. https://doi.org/10.1007/978-3-031-26908-0_15
Download citation
DOI: https://doi.org/10.1007/978-3-031-26908-0_15
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-031-26907-3
Online ISBN: 978-3-031-26908-0
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)